deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04680975

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSC)

A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Sponsor: Kadmon, a Sanofi Company

Conditions Diffuse Cutaneous Systemic Sclerosis
Interventions Belumosudil
Updated 17 times since 2021 Last updated: May 8, 2023 Started: Mar 3, 2021 Primary completion: May 10, 2022 Completion: Dec 19, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.

Other terminated trials from Kadmon, a Sanofi Company

See all terminations from Kadmon, a Sanofi Company

Other Diffuse Cutaneous Systemic Sclerosis trials with similar outcome

Browse all Diffuse Cutaneous Systemic Sclerosis trials

This PHASE2 trial investigates Diffuse Cutaneous Systemic Sclerosis and is currently terminated or withdrawn. Kadmon, a Sanofi Company leads this study, which shows 17 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Apr 2023 — Jul 2023 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  5. Feb 2023 — Apr 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  7. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  8. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  9. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  10. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  11. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kadmon, a Sanofi Company
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations